130 related articles for article (PubMed ID: 12752224)
1. Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas.
Kilicarslan AB; Ogus M; Arici C; Pestereli HE; Cakir M; Karpuzoglu G
APMIS; 2003 Mar; 111(3):439-43. PubMed ID: 12752224
[TBL] [Abstract][Full Text] [Related]
2. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults.
Fenton C; Patel A; Dinauer C; Robie DK; Tuttle RM; Francis GL
Thyroid; 2000 Apr; 10(4):349-57. PubMed ID: 10807064
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms.
Huang SM; Lee JC; Wu TJ; Chow NH
World J Surg; 2001 Mar; 25(3):302-6. PubMed ID: 11343180
[TBL] [Abstract][Full Text] [Related]
4. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer.
Lennard CM; Patel A; Wilson J; Reinhardt B; Tuman C; Fenton C; Blair E; Francis GL; Tuttle RM
Surgery; 2001 May; 129(5):552-8. PubMed ID: 11331447
[TBL] [Abstract][Full Text] [Related]
5. Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues.
Tanaka K; Kurebayashi J; Sonoo H; Otsuki T; Yamamoto Y; Ohkubo S; Yamamoto S; Shimozuma K
Surg Today; 2002; 32(9):761-8. PubMed ID: 12203051
[TBL] [Abstract][Full Text] [Related]
6. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
7. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors.
Lewy-Trenda I; Wierzchniewska-Ławska A
Pol J Pathol; 2002; 53(3):129-32. PubMed ID: 12476614
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma.
Tanaka K; Sonoo H; Kurebayashi J; Nomura T; Ohkubo S; Yamamoto Y; Yamamoto S
Clin Cancer Res; 2002 May; 8(5):1125-31. PubMed ID: 12006528
[TBL] [Abstract][Full Text] [Related]
9. Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas.
Millanta F; Lazzeri G; Vannozzi I; Viacava P; Poli A
Vet Pathol; 2002 Nov; 39(6):690-6. PubMed ID: 12450199
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
Soh EY; Duh QY; Sobhi SA; Young DM; Epstein HD; Wong MG; Garcia YK; Min YD; Grossman RF; Siperstein AE; Clark OH
J Clin Endocrinol Metab; 1997 Nov; 82(11):3741-7. PubMed ID: 9360534
[TBL] [Abstract][Full Text] [Related]
11. Expression of vascular endothelial growth factor in renal cell carcinomas.
Paradis V; Lagha NB; Zeimoura L; Blanchet P; Eschwege P; Ba N; Benoît G; Jardin A; Bedossa P
Virchows Arch; 2000 Apr; 436(4):351-6. PubMed ID: 10834538
[TBL] [Abstract][Full Text] [Related]
12. Co-regulatory potential of vascular endothelial growth factor-A and vascular endothelial growth factor-C in thyroid carcinoma.
Salajegheh A; Pakneshan S; Rahman A; Dolan-Evans E; Zhang S; Kwong E; Gopalan V; Lo CY; Smith RA; Lam AK
Hum Pathol; 2013 Oct; 44(10):2204-12. PubMed ID: 23845470
[TBL] [Abstract][Full Text] [Related]
13. Papillary carcinoma of the thyroid: evidence for a role for hepatocyte growth factor (HGF) in promoting tumour angiogenesis.
Scarpino S; D'Alena FC; Di Napoli A; Ballarini F; Prat M; Ruco LP
J Pathol; 2003 Feb; 199(2):243-50. PubMed ID: 12533838
[TBL] [Abstract][Full Text] [Related]
14. Higher plasma vascular endothelial growth factor levels correlate with menopause, overexpression of p53, and recurrence of breast cancer.
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Yamashita H; Fukuda M
Breast Cancer; 2003; 10(2):120-8. PubMed ID: 12736564
[TBL] [Abstract][Full Text] [Related]
15. Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma.
Li J; Teng L; Jiang H
Asia Pac J Clin Oncol; 2014 Jun; 10(2):149-52. PubMed ID: 23718885
[TBL] [Abstract][Full Text] [Related]
16. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
Bunone G; Vigneri P; Mariani L; Butó S; Collini P; Pilotti S; Pierotti MA; Bongarzone I
Am J Pathol; 1999 Dec; 155(6):1967-76. PubMed ID: 10595926
[TBL] [Abstract][Full Text] [Related]
17. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?
Koukourakis MI; Simopoulos C; Polychronidis A; Perente S; Botaitis S; Giatromanolaki A; Sivridis E
Anticancer Res; 2003; 23(2C):1673-80. PubMed ID: 12820439
[TBL] [Abstract][Full Text] [Related]
18. Recurrent thyroid cancers have more peritumoural lymphatic vasculature than nonrecurrent thyroid cancers.
Hakala T; Sand J; Kellokumpu-Lehtinen PL; Huhtala H; Leinonen R; Kholová I
Eur J Clin Invest; 2014 Sep; 44(9):825-32. PubMed ID: 25047155
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma.
Klein M; Vignaud JM; Hennequin V; Toussaint B; Bresler L; Plénat F; Leclère J; Duprez A; Weryha G
J Clin Endocrinol Metab; 2001 Feb; 86(2):656-8. PubMed ID: 11158026
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines.
Viglietto G; Maglione D; Rambaldi M; Cerutti J; Romano A; Trapasso F; Fedele M; Ippolito P; Chiappetta G; Botti G
Oncogene; 1995 Oct; 11(8):1569-79. PubMed ID: 7478581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
